Intravesical Ad-IFNα Causes Marked Regression of Human Bladder Cancer Growing Orthotopically in Nude Mice and Overcomes Resistance to IFN-α Protein-Reference-Cited by-同舟云学术

Intravesical Ad-IFNα Causes Marked Regression of Human Bladder Cancer Growing Orthotopically in Nude Mice and Overcomes Resistance to IFN-α Protein

Published:2004-09 Issue:3 Volume:10 Page:525-532
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Benedict William F.,Tao Ziming,Kim Chang-Soo,Zhang Xinqiao,Zhou Jain-Hua,Adam Liana,McConkey David J.,Papageorgiou Angela,Munsell Mark,Philopena Jennifer,Engler Heidrun,Demers William,Maneval Daniel C.,Dinney Colin P.N.,Connor Robert J.

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference19 articles.

1. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) tumors: 15-year outcome;Herr;J. Urol,2000

2. Current use and questions concerning intravesical bladder. Cancer Group for Superficial Bladder Cancer;Dalbagni;Urol. Clin. North Am,2002

3. Superficial bladder cancer: the role of interferon-alpha;Belldegrun;J. Urol,1998

4. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette–Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette–Guerin alone previously failed;O'Donnell;J. Urol,2001

5. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis;Izawa;Clin. Cancer Res,2002

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial;Journal of Urology;2024-07

2. The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward;Bladder Cancer;2024-06-18

3. An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer;Expert Opinion on Biological Therapy;2024-06-02

4. Documento multidisciplinar de consenso sobre el tratamiento actual del tumor vesical no-músculo invasor que no responde al tratamiento con bacilo Calmette-Guérin;Actas Urológicas Españolas;2024-05

5. Multidisciplinary consensus document on the current treatment of bacille Calmette-Guérin-unresponsive non-muscle invasive bladder tumor;Actas Urológicas Españolas (English Edition);2024-05